Contact Us

GENTAUR Europe

 GENTAUR Europe BVBA
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45 
Fax 0032 16 50 90 45
This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it. 

Gentaur Bulgaria

 GENTAUR BULGARIA
53 Iskar Str. 1191 Kokalyane, Sofia
Tel 0035924682280 
Fax 0035929830072
This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR France

     GENTAUR France SARL
    9, rue Lagrange, 75005 Paris 
    Tel 01 43 25 01 50 
    Fax 01 43 25 01 60
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Germany

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

      GmbH Marienbongard 20
    52062 Aachen Deutschland
    Tel (+49) 0241 56 00 99 68 
    Fax (+49) 0241 56 00 47 88 This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-family: Arial, Tahoma, Verdana, Helvetica; line-height: 15.59375px; ">
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="font-size: 12px; line-height: 1.3em;">

    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur London

     GENTAUR Ltd. 
    Howard Frank Turnberry House 
    1404-1410 High Road 
    Whetstone London N20 9BH 
    Tel 020 3393 8531 
    Fax 020 8445 9411
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Poland

     GENTAUR Poland Sp. z o.o. 

    ul. Grunwaldzka 88/A m.2

    81-771 Sopot, Poland
    Tel  058 710 33 44
    Fax 058 710 33 48 
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Nederland

     GENTAUR Nederland BV
    Kuiper 1 
    5521 DG Eersel Nederland
    Tel 0208-080893 
    Fax 0497-517897
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Gentaur Italy

     GENTAUR SRL IVA IT03841300167

    Piazza Giacomo Matteotti, 6, 24122 Bergamo
    Tel 02 36 00 65 93 
    Fax 02 36 00 65 94
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Spain

     GENTAUR Spain
    Tel 0911876558
    This email address is being protected from spambots. You need JavaScript enabled to view it." style="">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Genprice USA

    usa-flagGenprice Inc, Logistics
    547, Yurok Circle
    San Jose, CA 95123
    Phone/Fax: 

    (408) 780-0908 

    This email address is being protected from spambots. You need JavaScript enabled to view it.

    skype chat

    GENPRICE Inc. invoicing/ accounting:
    6017 Snell Ave, Suite 357
    San Jose, CA. 96123

     

    Gentaur Serbia

    serbiaSerbia, Macedonia FlagMacedonia, 

    montenegro-flagMontenegro, croatiaCroatia: 
    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Romania

    romGENTAUR Romania

    Tel 0035929830070 
    Fax 0035929830072
    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    GENTAUR Greece

    grGENTAUR Greece 

    Tel 00302111768494 
    Fax 0032 16 50 90 45

    This email address is being protected from spambots. You need JavaScript enabled to view it.">This email address is being protected from spambots. You need JavaScript enabled to view it.

    Other countries

    Other countries
    Luxembourg +35220880274
    Schweiz Züri +41435006251
    Danmark +4569918806
    Österreich +43720880899
    Ceská republika Praha +420246019719
    Ireland Dublin +35316526556
    Norge Oslo +4721031366
    Finland Helsset +358942419041
    Sverige Stockholm +46852503438
    Magyarország Budapest +3619980547

    seal-in-search-symantec

     

     

    Displaying items by tag: Gentaur
    Wednesday, 10 April 2013 00:00

    Duloxetine reduces painful neuropathy

    gene-modification-elisa-pcr-equrpment-monoclonal-antiAntidepressant duloxetine effectively treat peripheral neuropathy induced by chemotherapy showed a phase III clinical study published in the Journal of the American Medical Association.

    According to Ellen Smith of the University of Michigan in Ann Arbor, after 5 weeks of treatment, patients receiving duloxetine experienced a significant reduction in morbidity compared with placebo.

    Peripheral neuropathy occurs in 20-40% of patients treated with neurotoxic chemotherapy. Such fees are (paclitaxel, docetaxel, etc.)., Vinca alkaloids (vincristine, vinblastine) and platinum compounds (cisplatin, oxaliplatin, etc.).. The condition can persist for years after treatment and greatly reduced quality of life.

    Previous studies have shown that inhiborite reuptake of serotonin and norepinephrine (class of antidepressants) have the potential to influence the state. Duloxetine also is known to reduce morbidity and diabetic neuropathy.

    In order to clarify the properties of duloxetine, the researchers conducted a randomized, double-blind, placebo-controlled study in 220 patients with stage I or greater sensory neuropathy induced by anti-cancer therapy. All participants were over the age of 25 and assessed their painful 10-ball standard scale, three months after the completion of a chemotherapy course. Half the patients received duloxetine and half - placebo, allocation is done randomly. The soreness was re-assessed after the study.

    The end result of the study shows that 5-week treatment with duloxetine significantly reduces morbidity in peripheral neuropathy. This, in turn, enhances the quality of life and employability of patients. The benefits of duloxetine seem greatest for people who have completed chemotherapy with platinum compounds.

    The most common side effects of duloxetine documented during the study were fatigue, insomnia and nausea.
     
    Although good design of the study does not include follow-up of patients for an extended period, so it is impossible to tell how lasting are the effects of duloxetine in this indication.

    Published in News

    MultiGeneOptiMaxGradientThermalCyclerCommon laboratory research practice utilizes PCR to validate transgenic mouse lines. Validation of these lines typically involve multiple primer sets with various annealing temperatures leading to a very tedious and time consuming process. To allow researchers the opportunity to evaluate multiple transgenes within one PCR reaction, Gentaur offers the MultiGene OptiMax. Traditional thermal cyclers utilize a Peltier microchip block that is enabled for either homogeneous or gradient temperature mode. Additionally, with a traditional thermal cycler, a user can only utilize one annealing temperature per experiment. The new Gentaur MultiGene OptiMax has six distinct Peltier microchip elements that allow users to select up to six different annealing temperatures. This allows for the possibility to evaluate multiple genes in one experiment.

    • We now have a faster machine.
    • Brand new better than gradient function.
    • No more condensation issues
    • Custom block optimisation
    • Brand new PC Viewer

    For more details:

    PDF-Icon Operation Manual

    PDF-IconPresentation

    PDF-IconOptimax app note

    PDF-IconEnduro Catalog ll

    SPECIAL OFFER UNTIL THE END OF 2013

    Order Button1

     

     

    Published in Promos
    Tuesday, 09 April 2013 12:09

    The New XerumFree ™

    xerumfree-gentaurToday we officially introduce XerumFree™ XF205.

    After more then a year of development and testing internally and externally we kicked off production.

    The 5 times concentrated XF205 will bring you nothing but advantages. Both technically and commercially.  

     

    XerumFree™ XF205 will give you:

    Results
    Being concentrated, adding XF205 has a minimum impact on a basal medium. If you completely or partially (for autocrine growth) change the medium there will be only  little disruption of the concentration. 

    Ease of use
    In most cases 2% directly added to your ready basal medium will be sufficient, lower or higher amounts for special applications are no problem. Stored cold means ready to use; no more hassle to thaw and test. Just use it straight from the bottle.

    Consistency 
    Only fully defined media give predictable results: supplements with animal derived components and e.g. hydrolisates are not consistent. There is no need for batch testing; every bottle will be exactly the same. 

    Cost efficiency 
    Not only the savings on storage, testing and logistics count but using XerumFree™ means that experiments with expensive reagents or ingredients will not fail due to the medium. Repeatable results in your own or other facility are saving valuable time and budget. The extreme low protein content makes downstream processing cheaper.

    Freedom to operate
    No growth factors, no hormones, no animal components. Adding XF205 to a basal medium gives you a platform that is fully defined and the possibility to develop your application on top. Repeatable, safe and robust. 

    FDA-ready 
    Any application that will have to pass the regulatory bodies one day  (e.g. the FDA) benefits from the defined composition. The risks of presence of viruses or TSE is eliminated completely as no single component is of animal origin, and we certify that.

     


    Quality
    GMP produced is the best guarantee for quality. Produced in the Netherlands in a production facility authorized by the ministry of Health we can assure quality from bottle to bottle and from lot to lot.

    Universal
    XerumFree™ can be used with most cell lines, primary cells and stem cells. Making it the best choice to streamline cell culture routines and at the same time reducing the need for special media.

    Strategic choice
    The coming years are predicted to make FBS scarce, changing to XerumFree™ is a strategic choice for availability in the future.

    Weather it is to replace FBS or any other undefined supplement:
       
    XerumFree™ XF205 simply makes fully defined easy.

    Order Button1 

    Published in Promos

    brain research gentaur antibodiesU.S. President Barack Obama announced that it would invest $ 100 million in a new initiative which aims to highlight how the brain works, and help treat diseases such as epilepsy and Alzheimer's, the BBC reported. The "Human Genome" is transformed genetics. The same should be done with the knowledge of the human brain, Obama said in a speech at the White House.  

    "This is a great mystery waiting to be solved. BRAIN Initiative will give scientists the tools they need to get a dynamic picture of the brain to better understand how we think, learn and remember. And this knowledge will be transformation", said Obama.

    The project is called Brain Research through Advancing Innovative Neurotechnologies (BRAIN). Investment of 100 million dollars will be used to develop new technologies to explore how billions individual cells in the brain interact. Researchers will focus on how the brain record, store and process information, and will explore the relationship between brain function and behavior. Ethics Committee will supervise the research. 

    Obama said that investment in science is justified because it will help create jobs and boost the economy. In his words, basic research has been the engine of growth. The announcement of the funding comes after the recent news of the launch of a major European project in the field of neuroscience. Around 80 European research institutions, along with several non-EU countries will participate in the Human Brain Project, costing more than € 1 billion. The project will use the supercomputer models and simulations to reconstruct a virtual human brain.

    Published in News
    Wednesday, 03 April 2013 16:56

    Roadmap to an HIV Vaccine

    HIV-vaccine-gentaur-antibodiesBy investigating an African patient’s HIV infection, researchers have traced the development of an antibody that is effective at neutralizing many strains of HIV, according to a study published today (April 3) in Nature. The researchers—who identified the original HIV variant as well as the broadly neutralizing antibody, and pieced together their evolution over the course of infection—hope that a vaccine mimicking this process could encourage the development of such effective HIV-fighting antibodies.

    The new research provides “really in-depth information on how a particular type of broadly neutralizing antibody emerges over the course of a natural HIV infection,” said Leonidas Stamatatos, an immunologist at Seattle Biomedical Research Institute who did not participate in the study.

    Broadly neutralizing antibodies—able to block many strains of HIV from binding target cells—are notoriously rare: only about 20 percent of HIV-positive people ever generate such antibodies. One of the most attractive neutralizing targets is the HIV envelope protein (Env) that binds T cells, which is present on every variant of HIV. But Env is covered in sugar molecules that often mimic host structures, making it hard for the immune system to distinguish virus from self. In order to avoid an adverse autoimmune reaction, the body produces few B cells whose antibodies can recognize these common structures. One approach to developing an effective HIV vaccine is to stimulate these rare B cells, but because Env’s sequence can vary widely between HIV strains, researchers didn’t know much about the right Env variant for the job.

    In order to find an Env that could stimulate an antibody with broadly neutralizing potential, Barton Haynes at Duke University and researchers at the Center for HIV-AIDS Vaccine Immunology (CHAVI) set up eight acute infection clinics in Malawi, South Africa, Tanzania, Uganda, and one in North Carolina, where they could watch antibody and virus develop within weeks of infection.

    Haynes and his team found one patient who developed a broadly neutralizing antibody within 3 years of infection. The antibody, dubbed CH103, could block infection of target cells by 55 percent of the HIV virus particles they tested, which expressed a total of 196 different types of Env. Because the team had blood samples from the patient starting 4 weeks after infection, they could isolate the original antibody, CH103’s predecessor, as well as determine the sequence of the original Env protein that first spurred the antibody’s production.

    As HIV proteins accrue mutations during an infection, antibodies evolve to increase specificity and adapt to changing targets. Finding the antibody that bound the original Env allowed researchers to identify which mutations conferred broadly neutralizing activity to CH103 and identify mutations in Env that could have contributed to CH103’s development. Haynes and his colleagues hope to recreate the evolution of CH103-like antibodies using the right combination of Env variants in a vaccine.

    “The study provides important information on how one might design a rational vaccination strategy,”Dennis Burton, an immunologist at The Scripps Research Institute who did not participate in the study, wrote in an email to The Scientist. “[It’s] a significant leap.”

    An effective vaccine will need to elicit more than one type of antibody to block HIV infection, so Haynes and his team are also examining the evolution of broadly neutralizing antibodies and their corresponding HIV proteins in other patients, as well.

    Indeed, the bulk of the work is just beginning, said Stamatatos, who noted that the possible combinations of Env “are nearly infinite.” It’s also not clear yet whether the Env mutants should be given together, or provided sequentially in a fashion more akin to a natural infection. Haynes and his colleagues are currently beginning to test both strategies with different Env combinations in macaques and mice engineered to express human antibodies.

    H.-X. Liao et al., “Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus,”Nature, doi:10.1038/nature12053, 2013.

     

    Published in News

    avianOn 3 April 2013, the China Health and Family Planning Commission notified WHO of an additional four cases of human infection with influenza A(H7N9). The four patients are from Jiangsu province in eastern China. There is no link between the cases.

    To date, the total number of confirmed cases of human infection with influenza A(H7N9) virus in China is seven. Three confirmed cases were reported earlier from Shanghai and Anhui provinces, including two deaths.The patients include a 45-year-old woman with illness onset on 19 March 2013; a 48-year-old woman with illness onset on 19 March 2013; an 83-year-old man with illness onset on 20 March 2013; and a 32-year-old woman with illness onset on 21 March 2013. All of these patients are in a critical condition.

    More than 160 close contacts of these four cases in Jiangsu province are being closely monitored. Thus far, none of them have developed any symptoms of illness. Retrospective investigation is ongoing into two contacts of one of the cases reported earlier from Shanghai. Both of these contacts developed symptoms of illness; one died and the other recovered. No laboratory confirmation is available for these two contacts.

    The Chinese government is actively investigating this event and has heightened disease surveillance for early detection, diagnosis and treatment. Infection prevention and control has been strengthened in health-care settings. Communication efforts between human and animal health and industry sectors have increased. The government has advised the population to maintain good personal hygiene, including frequent handwashing and avoiding direct contact with sick or dead animals.

    WHO is in contact with national authorities and is following the event closely. The WHO-coordinated international response is also focusing on work with WHO Collaborating Centres for Reference and Research on Influenza and other partners to ensure that information is available and that materials are developed for diagnosis and treatment and vaccine development. No vaccine is currently available for this subtype of the influenza virus. Preliminary test results provided by the WHO Collaborating Centre in China suggest that the virus is susceptible to the neuraminidase inhibitors (oseltamivir and zanamivir).

    At this time there is no evidence of ongoing human-to-human transmission.

    WHO does not advise special screening at points of entry with regard to this event, nor does it recommend that any travel or trade restrictions be applied.

    For additional information, here is a full view of Gentaur's AIV-related products: 

    http://antibody-antibodies.com/search_full.php?search=AIV

    Published in News
    Monday, 08 April 2013 10:14

    Avian influenza H7N9 Promo

    uscn smallDear Clients, 

    We are happy to announce that another promo is available as of today: 

    1. Intended Use 

    Avian influenza virus H7N9 real time RT-PCR kit is used for the detection of gene H7 and gene N9 of avian influenza A subtype H7N9 in human nasal and pharyngeal secretions and bird fece by using real time PCR systems.

    2. Principle of Real-Time PCR

    The principle of the real-time detection is based on the fluorogenic 5’nuclease assay. During the PCR reaction, the DNA polymerase cleaves the probe at the 5’ end and separates the reporter dye from the quencher dye only when the probe hybridizes to the target DNA. This cleavage results in the fluorescent signal generated by the cleaved reporter dye, which is monitored real-time by the PCR detection system. The PCR cycle at which an increase in the fluorescence signal is detected initially (Ct) is proportional to the amount of the specific PCR product. Monitoring the fluorescence intensities during Real Time allows the detection of the accumulating product without having to re-open the reaction tube after the amplification.

    3. Product Description

    Highly pathogenic avian influenza (HPAI) caused by certain subtypes of influenza A virus in animal populations, particularly chickens, poses a continuing global human public health risk. Direct human infection by an avian influenza A (H5N1) virus was first recognized during the 1997 outbreak in Hong Kong. The avian influenza virus H7N9 is one subgroup among the larger group of H7 viruses. Some cases of human infection with H7N9 virus in China are confirmed till early April of 2013.

    Avian influenza virus H7N9 real time RT-PCR kit contains a specific ready-to-use system for the detection of avian influenza virus H7N9 by Reverse Transcription Polymerase Chain Reaction (RT-PCR) in the real-time PCR system. The master contains Super Mix for the specific amplification of the avian influenza virus H7N9 RNA. The reaction is done in one step real time RT-PCR. The first step is a reverse transcription (RT), during which the avian influenza virus H9 RNA is transcribed into cDNA. Afterwards, a thermostable DNA polymerase is used to amplify the specific gene fragments by polymerase chain reaction. Fluorescence is emitted and measured by the real time systems´ optical unit during the PCR. The detection of amplified avian influenza virus H7N9 DNA fragment is performed in fluorimeter channel FAM and HEX/VIC/JOE with the fluorescent quencher BHQ1. In addition, the kit contains a system to identify possible PCR inhibition by measuring the FAM fluorescence of the internal control (IC).

     4. Kit Contents

    Ref.

    Type of reagent

    Presentation 25rxns

    1

    2

    3

    4

    H7N9 Super Mix

    RT-PCR Enzyme Mix

    Molecular Grade Water

    H7N9 Positive Control  

    1 vial, 480ml

    1 vial, 28ml

    1 vial, 400μl

    1 vial, 30μl

    Analysis sensitivity: 1×103copies/ml;

    Note: Analysis sensitivity depends on the sample volume, elution volume, nucleic acid extraction methods and other factors .If you use the RNA extraction kits recommended, the analysis sensitivity is the same as it declares. However, when the sample volume is dozens or even hundreds of times greater than elution volume by some concentrating method, it can be much.

     

    Our Price: EUR 562

    Order Button1

     

    For additional information, here is a full view of Gentaur's AIV-related products: 

    http://antibody-antibodies.com/search_full.php?search=AIV

    Published in Promos
    Friday, 05 April 2013 16:15

    Seasonal Discount

    bottlesweb

    Dear Clients,

    From the 1st May until 30th June we will be offering 20% off the list price of our flashBAC kits.

     

    This includes:

    flashBAC 3,5,24 reaction kits.

    flashBAC GOLD 3,5,24 reaction kits.

    flashBAC ULTRA 3,5,24 reaction kits

    flashBAC PRIME 3,5,24 reaction kits.

     

    Hurry and call us today to secure your product!

    Published in Promos

    12846 bigFDA issued a permit for use of the new product Tenex Health - TX1 - a system to remove damaged or necrotic tissue. This application will allow a wide range of surgical procedures and interventions - abdominal surgery, orthopedic surgery, laparoscopy, Plastic and Reconstructive Surgery.

    The company currently offers products for the treatment of damaged tissue in the tendons in chronic tendon pain. INSTRUMENTS is the size of a pen and allows surgeons to supply energy in the form of ultrasonic waves through a needle that cuts and removes only the dead tissue. The whole procedure was carried out for 20 minutes under local anesthetic.

    Each year in the U.S. alone, the number of operations in tendon pain is over 10 million. Extending the testimony of multiple device will increase its applicability and convenience for physicians and patients, and the quality of the manipulation.

    According to Jill Foosball - Executive Director of Tenex Health, the device allows surgery at an early stage of the disease, allowing for faster, easier and more effective treatment and faster return patients to their daily activities. He said TH1 offers unique advantages - minimum invasiveness, which means speed, efficiency and safety of the procedures with minimal recovery time.

    The company designs and other products for minimally invasive surgery for the treatment of soft tissue injuries when bursitis, carpal tunnel surgery syndrome and post surgical adhesions.

    Published in News

    gene-therapy-gentaur-antibodiesWITHIN just eight days of starting a novel gene therapy, David Aponte's "incurable" leukaemia had vanished. For four other patients, the same happened within eight weeks, although one later died from a blood clot unrelated to the treatment, and another after relapsing. The cured trio, who were all previously diagnosed with usually fatal relapses of acute lymphoblastic leukaemia, have now been in remission for between 5 months and 2 years. Michel Sadelain of the Memorial Sloan-Kettering Cancer Center in New York, co-leader of the group that designed the trial, says that a second trial of 50 patients is being readied, and the team is looking into using the technique to treat other cancers.

    The key to the new therapy is identifying a molecule unique to the surface of cancer cells, then genetically engineering a patient's immune cells to attack it. In acute lymphoblastic leukaemia, immune cells called B-cells become malignant. The team were able to target a surface molecule known as CD19 that is only present on B-cells. Doctors extracted other immune cells called T-cells from the patients. These were treated with a harmless virus, which installed a new gene redirecting them to attack all cells bearing CD19. When the engineered T-cells were reinfused into the patients, they rapidly killed all B-cells, cancerous or otherwise.

    "The stunning finding was that in all five patients, tumours were undetectable after the treatment," says Sadelain. He reckons that the body should replenish the immune system with regular T-cells and healthy B-cells after a couple of months. However, the patients received donated bone marrow to ensure they could regrow a healthy immune system.

    The treatment is not the first to re-engineer T-cells to attack a form of leukaemia. Last year, an international company called Adaptimmune used the approach to treat 13 people with multiple myeloma – it left 10 in remission. "Although it's early days for these trials, the approach of modifying a patient's T-cells to attack their cancer is looking increasingly like one that will, in time, have a place alongside more traditional treatments," says Paul Moss of Cancer Research UK. Sadelain's team is now investigating the scope for attacking other cancers. Where no single surface molecule is unique to a cancer, he is seeking to target pairs of molecules that only occur together on cancer cells. In January, he demonstrated this approach by wiping out human prostate tumours implanted in mice, using T-cells engineered to target two surface molecules.

     

    Published in News